Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study

[1] Jack CR(2018)NIA-AA research framework: toward a biological definition of Alzheimer’s disease Alzheimer’s Dement 14 535-562

[2] Bennett DA(2009)Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 382-389

[3] Blennow K(2013)Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels J Alzheimers Dis 36 759-767

[4] Tapiola T(2014)Additional use of Aβ 42/Aβ 40 ratio with cerebrospinal fluid biomarkers P-Tau and Aβ 42 increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice J Alzheimer’s Dis 41 377-386

[5] Alafuzoff I(2017)The cerebrospinal fluid Aβ1-42/Aβ1-40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer’s disease in a clinical setting J Alzheimers Dis 60 561-576

[6] Herukka SK(2022)The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort Alzheimer’s Res Ther 14 1-9

[7] Slaets S(2017)Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment JAMA Neurol 74 1492-1501

[8] Le Bastard N(2015)Biomarkers of Alzheimer’s disease and mild cognitive impairment: a current perspective Adv Med Sci 60 76-82

[9] Martin JJ(2003)Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42 Arch Neurol 60 1202-1206

[10] Sauvée M(2016)Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting Eur J Nucl Med Mol Imaging 43 499-508

[1] Jack CR(2018)NIA-AA research framework: toward a biological definition of Alzheimer’s disease Alzheimer’s Dement 14 535-562

[2] Bennett DA(2009)Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain Arch Neurol 66 382-389

[3] Blennow K(2013)Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels J Alzheimers Dis 36 759-767

[4] Tapiola T(2014)Additional use of Aβ 42/Aβ 40 ratio with cerebrospinal fluid biomarkers P-Tau and Aβ 42 increases the level of evidence of Alzheimer’s disease pathophysiological process in routine practice J Alzheimer’s Dis 41 377-386

[5] Alafuzoff I(2017)The cerebrospinal fluid Aβ1-42/Aβ1-40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer’s disease in a clinical setting J Alzheimers Dis 60 561-576

[6] Herukka SK(2022)The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort Alzheimer’s Res Ther 14 1-9

[7] Slaets S(2017)Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment JAMA Neurol 74 1492-1501

[8] Le Bastard N(2015)Biomarkers of Alzheimer’s disease and mild cognitive impairment: a current perspective Adv Med Sci 60 76-82

[9] Martin JJ(2003)Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42 Arch Neurol 60 1202-1206

[10] Sauvée M(2016)Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting Eur J Nucl Med Mol Imaging 43 499-508